XML 25 R4.htm IDEA: XBRL DOCUMENT v3.23.2
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]        
Net sales $ 1,530.2 $ 1,373.9 $ 2,989.8 $ 2,715.1
Cost of sales 343.0 269.4 672.5 568.7
Gross profit 1,187.2 1,104.5 2,317.3 2,146.4
Selling, general, and administrative expenses 468.7 409.0 905.0 779.3
Research and development expenses 270.3 250.8 531.5 479.4
Intellectual property agreement and litigation expense (Note 3) 147.9 6.1 191.4 13.2
Change in fair value of contingent consideration liabilities (Note 7) (26.9) (20.9) (26.2) (23.8)
Operating income, net 327.2 459.5 715.6 898.3
Interest income, net (9.1) (0.9) (17.7) (1.5)
Other income, net (2.2) (4.3) (3.8) (1.0)
Income before provision for income taxes 338.5 464.7 737.1 900.8
Provision for income taxes 33.0 58.3 91.1 120.8
Net income 305.5 406.4 646.0 780.0
Net loss attributable to noncontrolling interest (Note 6) (1.6) 0.0 (1.6) 0.0
Net income attributable to Edwards Lifesciences Corporation $ 307.1 $ 406.4 $ 647.6 $ 780.0
Earnings per share:        
Basic (in dollars per share) $ 0.51 $ 0.65 $ 1.07 $ 1.26
Diluted (in dollars per share) $ 0.50 $ 0.65 $ 1.06 $ 1.24
Weighted-average number of common shares outstanding:        
Basic (in shares) 606.9 620.9 607.2 621.5
Diluted (in shares) 610.3 626.7 610.6 628.1